Adjuvant therapy with pegylated interferon alfa-2b (36months) versus low-dose interferon alfa-2b (18months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study
Titel:
Adjuvant therapy with pegylated interferon alfa-2b (36months) versus low-dose interferon alfa-2b (18months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study
Auteur:
Grob, Jean Jacques Jouary, Thomas Dréno, Brigitte Asselineau, Julien Gutzmer, Ralf Hauschild, Axel Leccia, Marie Thérèse Landthaler, Michael Garbe, Claus Sassolas, Bruno Herbst, Rudolf A Guillot, Bernard Chene, Genevieve Pehamberger, Hubert